AC Immune/$ACIU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AC Immune
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Ticker
$ACIU
Sector
Primary listing
Employees
153
Headquarters
Lausanne, Switzerland
Website
AC Immune Metrics
BasicAdvanced
$293M
-
-$0.64
1.65
-
Price and volume
Market cap
$293M
Beta
1.65
52-week high
$3.99
52-week low
$1.43
Average daily volume
272K
Financial strength
Current ratio
1.332
Quick ratio
1.306
Long term debt to equity
5.191
Total debt to equity
6.581
Interest coverage (TTM)
-301.86%
Profitability
EBITDA (TTM)
-61.591
Gross margin (TTM)
-117.89%
Net profit margin (TTM)
-174.67%
Operating margin (TTM)
-173.28%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$240,460
Management effectiveness
Return on assets (TTM)
-14.64%
Return on equity (TTM)
-50.98%
Valuation
Price to revenue (TTM)
8.105
Price to book
3.99
Price to tangible book (TTM)
12.24
Price to free cash flow (TTM)
-5.374
Free cash flow yield (TTM)
-18.61%
Free cash flow per share (TTM)
-0.551
Growth
Revenue change (TTM)
86.71%
Earnings per share change (TTM)
-22.87%
10-year revenue growth (CAGR)
-3.34%
3-year earnings per share growth (CAGR)
-18.71%
10-year earnings per share growth (CAGR)
1.22%
What the Analysts think about AC Immune
Analyst ratings (Buy, Hold, Sell) for AC Immune stock.
AC Immune Financial Performance
Revenues and expenses
AC Immune Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AC Immune stock?
AC Immune (ACIU) has a market cap of $293M as of October 17, 2025.
What is the P/E ratio for AC Immune stock?
The price to earnings (P/E) ratio for AC Immune (ACIU) stock is 0 as of October 17, 2025.
Does AC Immune stock pay dividends?
No, AC Immune (ACIU) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next AC Immune dividend payment date?
AC Immune (ACIU) stock does not pay dividends to its shareholders.
What is the beta indicator for AC Immune?
AC Immune (ACIU) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.